These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The chimpanzee as a model to test the side effects of human interferons. Schellekens H; de Reus A; vd Meide PH J Med Primatol; 1984; 13(5):235-45. PubMed ID: 6210368 [TBL] [Abstract][Full Text] [Related]
3. [Interferons and autoimmune diseases]. Niino M; Miyazaki Y Brain Nerve; 2013 Nov; 65(11):1381-8. PubMed ID: 24200616 [TBL] [Abstract][Full Text] [Related]
4. [Problems on interferon therapy of chronic hepatitis C]. Miyaki K; Yamanaka M Nihon Naika Gakkai Zasshi; 1994 Feb; 83(2):252-8. PubMed ID: 7525801 [No Abstract] [Full Text] [Related]
5. Interferons: from molecular biology to man. Part 3. Interferons and disease. Balkwill FR Microbiol Sci; 1986 Sep; 3(9):281-4. PubMed ID: 2484751 [TBL] [Abstract][Full Text] [Related]
6. [Interferons and their physiological significance]. Eggen BM Tidsskr Nor Laegeforen; 1985 Oct; 105(28):1971-3. PubMed ID: 2416076 [No Abstract] [Full Text] [Related]
7. [Problems on "interferon" as a medicine: -- a view point of an investigatar participating in its developement-- (author's transl)]. Kohno S Tanpakushitsu Kakusan Koso; 1976 Apr; 21(4):328-333. PubMed ID: 1034951 [No Abstract] [Full Text] [Related]
8. [Changes in the monooxygenase activity of the mouse liver by the activity of high-molecular immunomodulators]. Galkin BN; Filippova TO; Golovenko NIa Vopr Med Khim; 1983; 29(6):60-3. PubMed ID: 6199895 [TBL] [Abstract][Full Text] [Related]
9. [Cutaneous side effects of interferons]. Paquet P; Piérard-Franchimont C; Arrese JE; Piérard GE Rev Med Liege; 2001 Oct; 56(10):699-702. PubMed ID: 11765581 [TBL] [Abstract][Full Text] [Related]
10. Mood disorder associated with gastrointestinal and liver diseases: are there many challenges? Gadit AA J Pak Med Assoc; 2010 Dec; 60(12):1064-5. PubMed ID: 21381565 [No Abstract] [Full Text] [Related]
11. [The role and therapeutic use of interferons in leishmaniasis (a review of the literature)]. Fediainova IE Med Parazitol (Mosk); 1992; (5-6):57-61. PubMed ID: 1284397 [No Abstract] [Full Text] [Related]
12. In the coming year we should abandon interferons and glatiramer acetate as first line therapy for MS: commentary. Hutchinson M Mult Scler; 2013 Jan; 19(1):29-30. PubMed ID: 23303882 [No Abstract] [Full Text] [Related]
13. In the coming year we should abandon interferons and glatiramer acetate as first line therapy for MS: no. Hillert J Mult Scler; 2013 Jan; 19(1):26-8. PubMed ID: 23303881 [No Abstract] [Full Text] [Related]
14. [Interferons in medicine]. Lucivero G Recenti Prog Med; 1990 May; 81(5):329-36. PubMed ID: 1696020 [TBL] [Abstract][Full Text] [Related]
15. Interferons and cancer: what is the present position? Priestman TJ Radiography; 1983 Jan; 49(577):17-9. PubMed ID: 6191356 [No Abstract] [Full Text] [Related]
16. Neuropsychiatric complications of interferons: classification, neurochemical bases, and management. Malek-Ahmadi P; Hilsabeck RC Ann Clin Psychiatry; 2007; 19(2):113-23. PubMed ID: 17612851 [TBL] [Abstract][Full Text] [Related]
17. Association of Raynaud's syndrome with interferons. A meta-analysis. Mohokum M; Hartmann P; Schlattmann P Int Angiol; 2012 Oct; 31(5):408-13. PubMed ID: 22990501 [TBL] [Abstract][Full Text] [Related]
20. Present status and future problems of interferon in the treatment of hematological malignancies. Kimura K Nihon Ketsueki Gakkai Zasshi; 1985 Dec; 48(8):1677-87. PubMed ID: 2425532 [No Abstract] [Full Text] [Related] [Next] [New Search]